You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 38 Serum proteomics signature and its association with immune-related toxicities and survival in patients with non-small cell lung cancers (NSCLC) receiving immunotherapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
38 Serum proteomics signature and its association with immune-related toxicities and survival in patients with non-small cell lung cancers (NSCLC) receiving immunotherapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 202315607
Dec 20232905
Jan 20242402
Feb 20242204
Mar 20242003
Apr 20243007
May 20242401
Jun 20243105
Jul 20241601
Aug 20241205
Sep 20241603
Oct 20242203
Nov 20242204
Dec 20243606
Jan 20253007
Feb 2025105
Mar 2025002
Apr 2025004
May 2025003
Jun 2025005
Total491082